NCT01711346 - A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

November 30, 2014

Conditions

Focus: Assess Post Infusion Viability of S303 RBCs

Interventions

BIOLOGICAL

S303 Red Blood Cells (RBCs)

Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.

BIOLOGICAL

Conventional, untreated Red Blood Cells (RBCs)

Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.

Trial Locations (2)

53201

BloodCenter of Wisconsin Inc., Milwaukee

45267-0055

Hoxworth Blood Center, Cincinnati